AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Cancer drugs such as Imatinib (for the treatment of chronic myeloid leukemia), cetuximab, lapatinib, gefitinib (for the treatment of breast, prostate, kidney and ovarian cancers) also target both AKT and ERK in order to inhibit phosphorylation of FoxO3 [60].